| Title: |
Combination Treatment with Verinurad and Allopurinol in CKD:A Randomized Placebo and Active Controlled Trial |
| Authors: |
Heerspink, Hiddo J.L.; Stack, Austin G.; Terkeltaub, Robert; Jongs, Niels; Inker, Lesley A.; Bjursell, Magnus; Maklad, Noha; Perl, Shira; Eklund, Olof; Rikte, Tord; Sjöström, C. David; Perkovic, Vlado |
| Source: |
SAPPHIRE Investigators, Heerspink, H J L, Stack, A G, Terkeltaub, R, Jongs, N, Inker, L A, Bjursell, M, Maklad, N, Perl, S, Eklund, O, Rikte, T, Sjöström, C D & Perkovic, V 2024, 'Combination Treatment with Verinurad and Allopurinol in CKD : A Randomized Placebo and Active Controlled Trial', Journal of the American Society of Nephrology, vol. 35, no. 5, pp. 594-606. https://doi.org/10.1681/ASN.0000000000000326 |
| Publication Year: |
2024 |
| Collection: |
University of Groningen research database |
| Subject Terms: |
Albuminuria; Chronic Kidney Disease; Kidney Dysfunction; Randomized Controlled Trials |
| Description: |
Background: Hyperuricemia is associated with elevated risks of cardiovascular and chronic kidney disease (CKD). Since inhibition of urate transporter 1 has been suggested to be potentially nephroprotective, we performed a phase 2b study to assess albuminuria-lowering effects of the urate transporter 1 inhibitor verinurad combined with the xanthine oxidase inhibitor allopurinol in patients with CKD and hyperuricemia. Methods: In this randomized placebo and active controlled trial, we enrolled participants with serum urate concentrations ≥6.0 mg/dl, eGFR ≥25 ml/min per 1.73 m 2 , and a urinary albumin-creatinine ratio (UACR) 30-5000 mg/g to one of five treatment arms: placebo, placebo+allopurinol 300 mg/day, verinurad 3 mg+allopurinol 300 mg/day, verinurad 7.5 mg+allopurinol 300 mg/day, or verinurad 12 mg+allopurinol 300 mg/day in a 1:1:1:1:1 ratio. The primary end point was the change in UACR from baseline to 34 weeks. Secondary end points were changes from baseline in UACR at week 60 and changes in serum urate and eGFR at weeks 34 and 60. Results: Between August 2019 and November 2021, 861 adults with CKD (mean age 65 years, 33.0% female, mean eGFR 48 ml/min per 1.73 m 2 , median UACR 217 mg/g) were enrolled. At 34 weeks, the geometric mean percentage change in UACR from baseline did not differ among treatment groups (16.7%, 95% confidence interval [CI],-0.6 to 37.1 in the 3 mg group, 15.0% [95% CI,-1.85 to 34.6] in the 7.5 mg group, 14.0% [95% CI,-3.4 to 34.4] in the 12 mg group versus 9.9% [95% CI,-6.6 to 29.4] in the allopurinol group, and 37.3% [95% CI, 16.6 to 61.8] in the placebo group). UACR and eGFR change from baseline did not differ among treatment groups after 60 weeks. Verinurad/allopurinol combination dose-dependently reduced serum urate concentrations compared with placebo. The proportion of patients with adverse events and serious adverse events was balanced among treatment groups. Conclusions: Verinurad in combination with allopurinol did not decrease UACR or eGFR decline, but further reduced ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
1046-6673; 1533-3450 |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/38564654; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/11370/3337cb40-9da9-4532-ba95-d4c30b5c4b9a; info:eu-repo/semantics/altIdentifier/pissn/1046-6673; info:eu-repo/semantics/altIdentifier/eissn/1533-3450 |
| DOI: |
10.1681/ASN.0000000000000326 |
| Availability: |
https://hdl.handle.net/11370/3337cb40-9da9-4532-ba95-d4c30b5c4b9a; https://research.rug.nl/en/publications/3337cb40-9da9-4532-ba95-d4c30b5c4b9a; https://doi.org/10.1681/ASN.0000000000000326; https://pure.rug.nl/ws/files/1104884854/combination_treatment_with_verinurad_and.10.pdf; https://www.scopus.com/pages/publications/85192028768 |
| Rights: |
info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.27FCC9DD |
| Database: |
BASE |